Johnson & Johnson ($JNJ) won a split decision in Philadelphia court Friday, in the latest Risperdal lawsuit to go to trial. A jury decided that J&J did fail to warn doctors that the antipsychotic drug could cause breast development in boys, Reuters reports. But the plaintiff in the case didn't prove his own breast development was caused by Risperdal, the jury found. No damages were awarded. Report